MyoKardia, Inc. is pioneering a precision medicine approach to treating genetic heart disease.
By combining leading-edge cardiovascular genetics with recent advances in heart muscle biochemistry, MyoKardia seeks to revolutionize the treatment of cardiomyopathies and make a meaningful difference in the lives of the millions of people suffering from cardiovascular diseases.
News & Events
MyoKardia, Inc. Completes $46 Million Series B Financing
MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy
MyoKardia CEO Tassos Gianakakos Discusses Company’s Precision Medicine Approach to Cardiovascular Disease on Fox Business News